NASDAQ:ALNY

Alnylam Pharmaceuticals Stock Insider Trading

Healthcare > Biotechnology

Buy ALNY

*Your capital is at risk

$286.12

-9.51 (-3.22%)

At Close: Jun 02, 2026

Alnylam Pharmaceuticals Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be negative at -64.22. In total, the insiders bought 59.77K and sold 20.65K ALNY shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	-64.22
● Buy	59.77K shares
● Sell	20.65K shares
24% Buy Activity Weak Negative Correlation
Buy Signal Low Confidence Mar 02, 2026 Analysis Breakdown: Signal is highly questionable due to a strongly contradictory negative Insider Power Score of -64.22. Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date	Type	Person	Role	Amount
Mar 04, 2026 Sell	Common Stock S-Sale	Garg Pushkal EVP Chief R&d	Officer	272 Value: $88.4K
Mar 04, 2026 Sell	Common Stock S-Sale	Garg Pushkal EVP Chief R&d	Officer	208 Value: $67.7K
Mar 04, 2026 Sell	Common Stock S-Sale	Greenstreet Yvonne Chief Executive Officer	CEO / President	135 Value: $43.1K
Mar 04, 2026 Sell	Common Stock S-Sale	Greenstreet Yvonne Chief Executive Officer	CEO / President	129 Value: $41.3K
Mar 04, 2026 Sell	Common Stock S-Sale	Greenstreet Yvonne Chief Executive Officer	CEO / President	345 Value: $112.1K
Mar 04, 2026 Sell	Common Stock S-Sale	Greenstreet Yvonne Chief Executive Officer	CEO / President	265 Value: $86.3K
Mar 04, 2026 Sell	Common Stock S-Sale	Poulton Jeffrey V. EVP, Chief Financial Officer	C-Suite Officer	109 Value: $34.9K
Mar 04, 2026 Sell	Common Stock S-Sale	Poulton Jeffrey V. EVP, Chief Financial Officer	C-Suite Officer	230 Value: $73.8K
Mar 04, 2026 Sell	Common Stock S-Sale	Poulton Jeffrey V. EVP, Chief Financial Officer	C-Suite Officer	309 Value: $99.4K
Mar 04, 2026 Sell	Common Stock S-Sale	Poulton Jeffrey V. EVP, Chief Financial Officer	C-Suite Officer	374 Value: $120.8K
Mar 04, 2026 Sell	Common Stock S-Sale	Poulton Jeffrey V. EVP, Chief Financial Officer	C-Suite Officer	291 Value: $94.5K
Mar 04, 2026 Sell	Common Stock S-Sale	Poulton Jeffrey V. EVP, Chief Financial Officer	C-Suite Officer	223 Value: $72.6K
Mar 04, 2026 Sell	Common Stock S-Sale	Tanguler Tolga EVP, Chief Commercial Officer	Officer	106 Value: $33.8K
Mar 04, 2026 Sell	Common Stock S-Sale	Tanguler Tolga EVP, Chief Commercial Officer	Officer	102 Value: $32.6K
Mar 04, 2026 Sell	Common Stock S-Sale	Tanguler Tolga EVP, Chief Commercial Officer	Officer	215 Value: $69.0K
Mar 04, 2026 Sell	Common Stock S-Sale	Tanguler Tolga EVP, Chief Commercial Officer	Officer	289 Value: $93.0K
Mar 04, 2026 Sell	Common Stock S-Sale	Tanguler Tolga EVP, Chief Commercial Officer	Officer	350 Value: $113.1K
Mar 04, 2026 Sell	Common Stock S-Sale	Tanguler Tolga EVP, Chief Commercial Officer	Officer	272 Value: $88.4K
Mar 04, 2026 Sell	Common Stock S-Sale	Tanguler Tolga EVP, Chief Commercial Officer	Officer	208 Value: $67.7K
Mar 04, 2026 Sell	Common Stock S-Sale	Fitzgerald Kevin Joseph Cso & EVP, Head Of Research	Officer	29 Value: $9K
Mar 04, 2026 Sell	Common Stock S-Sale	Fitzgerald Kevin Joseph Cso & EVP, Head Of Research	Officer	59 Value: $18.9K
Mar 04, 2026 Sell	Common Stock S-Sale	Fitzgerald Kevin Joseph Cso & EVP, Head Of Research	Officer	79 Value: $25.4K
Mar 04, 2026 Sell	Common Stock S-Sale	Fitzgerald Kevin Joseph Cso & EVP, Head Of Research	Officer	96 Value: $31.0K
Mar 04, 2026 Sell	Common Stock S-Sale	Fitzgerald Kevin Joseph Cso & EVP, Head Of Research	Officer	210 Value: $68.0K
Mar 04, 2026 Sell	Common Stock S-Sale	Fitzgerald Kevin Joseph Cso & EVP, Head Of Research	Officer	57 Value: $18.6K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT ALNYLAM PHARMACEUTICALS

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection f...

Read Full Profile Here